LINAC-based radiosurgery for melanoma, sarcoma and renal cell carcinoma brain metastases.
Journal
Journal of neurosurgical sciences
ISSN: 1827-1855
Titre abrégé: J Neurosurg Sci
Pays: Italy
ID NLM: 0432557
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
pubmed:
8
9
2016
medline:
15
12
2020
entrez:
8
9
2016
Statut:
ppublish
Résumé
The aim of this study was to report response, overall survival (OS) and toxicity in patients with radioresistant brain metastases (BM) treated with stereotactic radiosurgery (SRS). Patients with renal cell carcinoma, melanoma and sarcoma with one to four brain metastases received SRS without whole brain radiotherapy. Fifty patients with 77 BM were treated. 46 (92%) patients with 71 BM were evaluable. Median follow-up was 67 months and median OS 11.8 months. At the time of analysis all patients had died. Brain control was conditioned by response to SRS (P<0.0001), while OS by histology (renal cell carcinoma versus melanoma and sarcoma) (P=0.04) and status of the tumour outside the brain (P=0.05). Treatment was well tolerated without more than grade 2 acute toxicity. Treatment of BM from radioresistant tumors with SRS assures good brain control and OS with low toxicity. Our data suggest a better prognosis associated to renal cell carcinoma histology.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to report response, overall survival (OS) and toxicity in patients with radioresistant brain metastases (BM) treated with stereotactic radiosurgery (SRS).
METHODS
METHODS
Patients with renal cell carcinoma, melanoma and sarcoma with one to four brain metastases received SRS without whole brain radiotherapy.
RESULTS
RESULTS
Fifty patients with 77 BM were treated. 46 (92%) patients with 71 BM were evaluable. Median follow-up was 67 months and median OS 11.8 months. At the time of analysis all patients had died. Brain control was conditioned by response to SRS (P<0.0001), while OS by histology (renal cell carcinoma versus melanoma and sarcoma) (P=0.04) and status of the tumour outside the brain (P=0.05). Treatment was well tolerated without more than grade 2 acute toxicity.
CONCLUSIONS
CONCLUSIONS
Treatment of BM from radioresistant tumors with SRS assures good brain control and OS with low toxicity. Our data suggest a better prognosis associated to renal cell carcinoma histology.
Identifiants
pubmed: 27603406
doi: 10.23736/S0390-5616.16.03745-0
pii: R38Y9999N00A16090701
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM